shutterstock_721217131_iryna_imago
Iryna Imago / Shutterstock.com
3 January 2020AmericasRory O'Neill

Generics makers appeal pay-for-delay ban to Ninth Circuit

A group of generics manufacturers yesterday, December 2 asked the US Court of Appeals for the Ninth Circuit to reverse California’s ban on pay-for-delay deals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
9 October 2019   California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
Americas
13 January 2020   California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.
Americas
25 February 2020   The US Court of Appeals for the Ninth Circuit has blocked generics makers’ request to halt California’s ban on pay-for-delay deals while they challenge the legislation.

More on this story

Americas
9 October 2019   California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
Americas
13 January 2020   California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.
Americas
25 February 2020   The US Court of Appeals for the Ninth Circuit has blocked generics makers’ request to halt California’s ban on pay-for-delay deals while they challenge the legislation.

More on this story

Americas
9 October 2019   California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
Americas
13 January 2020   California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.
Americas
25 February 2020   The US Court of Appeals for the Ninth Circuit has blocked generics makers’ request to halt California’s ban on pay-for-delay deals while they challenge the legislation.